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Abstract
Activation of the androgen receptor (AR) is a key step in the development of prostate cancer (PCa). Several
mechanisms have been identified in AR activation, among them signal transducer and activator of transcription 3
(STAT3) signaling. Disruption of STAT3 activity has been associated to cancer progression. Recent studies suggest
that heme oxygenase 1 (HO-1) may play a key role in PCa that may be independent of its catalytic function. We sought
to explore whether HO-1 operates on AR transcriptional activity through the STAT3 axis. Our results display that HO-1
induction in PCa cells represses AR activation by decreasing the prostate-specific antigen (PSA) promoter activity and
mRNA levels. Strikingly, this is the first report to show by chromatin immunoprecipitation analysis that HO-1 associ-
ates to gene promoters, revealing a novel function for HO-1 in the nucleus. Furthermore, HO-1 and STAT3 directly
interact as determined by co-immunoprecipitation studies. Forced expression of HO-1 increases STAT3 cyto-
plasmic retention. When PCa cells were transfected with a constitutively active STAT3 mutant, PSA and STAT3
downstream target genes were abrogated under hemin treatment. Additionally, a significant decrease in pSTAT3
protein levels was detected in the nuclear fraction of these cells. Confocal microscopy images exhibit a de-
creased rate of AR/STAT3 nuclear co-localization under hemin treatment. In vivo studies confirmed that STAT3
nuclear delimitation was significantly decreased in PC3 tumors overexpressing HO-1 grown as xenografts in nude
mice. These results provide a novel function for HO-1 down-modulating AR transcriptional activity in PCa, interfering
with STAT3 signaling, evidencing its role beyond heme degradation.
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Introduction
Prostate cancer (PCa) is the second leading cause of cancer-associated
death in men. Androgens and the androgen receptor (AR) are criti-
cal in PCa development and progression [1]. AR-mediated transcrip-
tion requires the formation of an activation complex through the
recruitment of several co-activators of transcription and transcrip-
tion factors, which will ultimately determine target activation [2].
The potency and selectivity for subreactions of transcription reside
in the co-activators, and thus, they are critically important for tissue-
selective gene function [3,4]. There is an increasing recognition that
co-activators also regulate a variety of biological processes outside
of the nucleus such as mRNA translation, mitochondrial function,
invasion, and motility [3].
Cytokines have been implicated in the modulation of AR activation
as well as the growth and differentiation of PCa [5]. Oxidative damage
also plays key roles in prostate carcinogenesis [6]. Elevated reactive
oxygen species generation has been associated with inflammation
and malignant transformation [7]. An altered cellular microenviron-
ment could induce posttranslational changes in certain co-regulators
with different compartmental functions [3,4].
The induction of heme oxygenase 1 (HO-1), the rate-limiting
enzyme in heme degradation, represents a key event in cellular
responses to pro-oxidative and pro-inflammatory insults [8]. It partici-
pates in the maintenance of cellular homeostasis by reducing oxidative
injury, attenuating inflammation and regulating cell proliferation.
There are differences in HO-1 basal expression profiles among cells
and tissues and its pleiotropic effects to restore homeostasis. Thus,
HO-1 has been proposed to act as a biosensor regulating cell destina-
tion [9]. Previous reports from our laboratory documented for the first
time the nuclear expression of HO-1 in human primary prostate carci-
nomas [10]. We also showed that HO-1 nuclear localization inhibits
cell proliferation, migration, and invasion in vitro and that HO-1
impairs tumor growth in vivo [11]. In addition, we previously estab-
lished a key role for HO-1 as a modulator of the angiogenic switch
in prostate carcinogenesis [12]. Moreover, we showed evidence that
the anti-angiogenic function of HO-1 was mediated by repression of
nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB)
signaling pathway [12].
A better understanding of the molecular mechanisms underlying the
development of PCa may help to identify novel targets for pharmaco-
logical intervention in this disease. In this regard, the nature of signal
transduction pathways whose aberrant activity promotes the unreg-
ulated growth and survival of PCa cells and tumors is continuously
under study. The signal transducer and activator of transcription
3 (STAT3) modulates the expression of genes induced by interleukins
(ILs), such as IL-6, and this transcription factor associates to AR and
activates AR response elements [13,14]. It has been reported that
STAT3 is constitutively active in PCa and its expression was corre-
lated with the malignant severity of these tumors [13,15]. Further-
more, STAT3 inhibitor PIAS3 can compete with AR for STAT3
binding, thus repressing the expression of STAT3-mediated AR
downstream target genes [16]. These data suggest a direct interac-
tion and cross talk between cytokines and AR signaling pathways in
PCa [17].
Here, we present data that support a novel function for HO-1 in the
nucleus. We found that HO-1 associates to the proximal promoter of
genes involved in PCa progression. We also show a cross talk between
AR/STAT3 and HO-1 pathways. These data further support the anti-
tumorigenic properties of HO-1 in PCa.
Materials and Methods
Cell Culture, Treatments, Reagents, and Antibodies
LNCaP and PC3 cells were obtained from the American Type Cul-
ture Collection (Manassas, VA) and were routinely cultured in RPMI
1640 (Invitrogen, Buenos Aires, Argentina) supplemented with 10%
FBS. PC3 stable transfected cells (PC3HO-1 and PC3pcDNA3) were
previously described [11].
Testosterone undecanoate was purchased from SCHERING
(Buenos Aires, Argentina). Hemin was obtained from Sigma-Aldrich
(St Louis, MO) and IL-6 from Endogen (Thermo Fisher Scientific
Inc, Rockford, IL). Cells were incubated 24 hours in phenol red-
free RPMI media containing 10% charcoal-stripped FBS and then
were exposed to testosterone (10 μM), hemin (80 μM), and/or IL-6
(10 ng/ml) by 24 hours.
Polyclonal anti–HO-1 and monoclonal anti–HO-1 were from
Stressgen Biotechnologies Corp (San Diego, CA). Anti-AR, laminin
A/C, and anti-STAT3 antibodies were from Santa Cruz Biotechnology
(Santa Cruz, CA). Anti–β-actin antibody was from Sigma-Aldrich.
Anti-mouse and anti-rabbit secondary antibodies were from Amersham
(GE Healthcare, Piscataway, NJ). Anti-pSTAT3 antibody was from
Cell Signaling Technology (Beverly, MA). Alexa Fluor 488 goat
anti-mouse and Alexa Fluor 555 goat anti-rabbit antibodies were from
Molecular Probes (Invitrogen).
Plasmids and PSA Luciferase Cloning
The human pcDNA3 AR5 expression vector was kindly provided
by Dr G. Jenster (Department of Urology, Josephine Nefkens Insti-
tute, Erasmus University Rotterdam, Rotterdam, The Netherlands).
The human pcDNA3 HO-1 expression vector was kindly provided
by Dr M. Mayhofer (Clinical Institute for Medical and Chemical
Laboratory Diagnostics, University of Vienna, Vienna, Austria). The
dominant negative STAT3 vector (STAT3 DN) and the constitutively
activated STAT3 mutant (STAT-C) were kindly provided by Dr James
Darnell (Rockefeller University, New York, NY). The pSPAX2,
pMD2G, pSEW-shSTAT3.1, pSEW-shSTAT3.2, and pSEW-GL2
were kindly provided by Bernd Groner (Georg Speyer Haus, Institute
for Biomedical Research, Frankfurt, Germany).
The pGL3 prostate-specific antigen (PSA) luciferase vector was gen-
erated. Briefly, long PCR Enzyme Mix (Fermentas; Thermo Fisher
Scientific Inc, Rockford, IL) was used to amplify the PSA promoter
region (4.3-kb upstream the transcription start site) from human
DNA using specific primers: 5′ATTCTCGAGTTCATGTTCACAT-
TAGTACACCTTGC3′ and 5′GTTAAGCTTTGCTGCTGGAGG-
CTGGAC3′. Cycling included a step at 94°C for 2 minutes followed
by 10 cycles of 94°C to 20 seconds, 68°C to 3 minutes and 25 cycles
of 94°C to 20 seconds, 68°C to 3 minutes + 10 seconds per cycle, with
a final step at 68°C to 10 minutes. The pGL3 empty vector and the
polymerase chain reaction (PCR) product were purified (Qiaquick
PCR Purification Kit; QIAGEN, Valencia, CA) and digested with
0.5 U/μl of Hind III and XhoI (37°C, overnight; Fermentas). After
pGL3 dephosphorylation [calf intestinal alkaline phosphatase (CIAP),
0.034 U/μl; Invitrogen], the PCR-digested fragment and vector (3:1)
were ligated using T4 DNA Ligase (Invitrogen) and used to transform
competent Escherichia coli DH5α. PSA promoter insert was checked
on the clones by digestion and sequencing using specific primers
(F1:5′ATTCTCGAGGGCACACGGCACCTGTAATCC3′, F2:5′
TTCTCGAGCTCACTGTGCTTGGAGTTTACCTG3′, F3:5′
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ATTCTCGAGGGTGTCATCCACTCATCATCCAG3′, F4:5′
ATTCTCGAGTTCATGTTCACATTAGTACACCTTGC3′,
R1:5′GTTAAGCTTTGCTGCTGGAGGCTGGAC3′, R2:5′
GGCAGGAGAATCACTTGAAC3′, R3:5′GCTCACGCCTGT-
AATCCCAAC3′).
Transfections and Luciferase Assay
LNCaP and PC3 cells were seeded on 12-well plates (1.2 × 105 cells
per well). Expression vectors (2 μg) and/or PSA luciferase plasmid
(2 μg) were co-transfected in PC3 or LNCaP cells using Lipofectamine
2000 (Invitrogen). Luciferase activity was determined by the Luciferase
Assay System (Promega, Madison, WI) in a Glomax luminometer
(Promega). Transfections were performed in triplicate and each experi-
ment was repeated at least three times. Data were normalized to total
protein determined by the Bradford assay.
RNA Isolation and Reverse Transcription–Quantitative PCR
Total RNA was isolated with TRIREAGENT (Molecular Re-
search Center, Cincinnati, OH) according to the manufacturer’s
protocol. cDNAs were synthesized with RevertAid Premium First
Strand cDNA Synthesis Kit (Fermentas) and used for real-time PCR
amplification with Taq DNA Polymerase (Invitrogen) in a DNA
Engine Opticon (MJ Research, Esco Technologies, Inc, Hatboro, PA).
Primers sequences used were given as follows: HO-1, 5′GAGTGTA-
AGGACCCATCGGA3′ and 5′GCCAGCAACAAAGTGCAAG3′;
survivin, 5′GGAGCCAGATGACGACCCCA3′ and 5′AGCGCAA-
CCGGACGAATGCT3′; cyclin D1, 5′GCGGAGGAGAACAAA-
CAGAT3′ and 5′TGAGGCGGTAGTAGGACAGG3′; Bcl-xL, 5′
GGTATTGGTGAGTCGGATCG3′ and 5′TTCCACAAAAG-
TATCCCAGC3′; STAT3, 5′AGCATCCTGAAGCTGACC-
CAGGT3′ and 5′TCGGCAGGTCAATGGTATTGCTGC3′;
PSA, 5′GTTGTCTTCCTCACCCTGTCC3′ and 5′ACTGCCC-
TGCCACGAGAG3′; uPA, 5′GAGATCACTGGCTTTGGAAAA3′
and 5′CCAGCTCACAATTCCAGTCA3′; and β-actin, 5′CGGTT-
GGCCTTAGGGTTCAGGGGGG3′ and 5′GTGGGCCGCTCT-
AGGCACCA3′. Data were analyzed by Opticon-3 software and
normalized to β-actin and control. Errors were calculated as previously
described [11].
Immunoblot Analysis
The nuclear/cytoplasmic lysates and immunoblot analysis were
carried out as previously described [10].
Co-immunoprecipitation
LNCaP cells were treated as described above and harvested in lysis
buffer [20 mM Tris-HCl (pH 8), 137 mM NaCl, 10% glycerol,
2 mM EDTA, 1% Triton X-100, 1× protease inhibitor mixture
(Sigma-Aldrich), 100 μg/ml PMSF, 20 mM NaF, and 1 mM
NaVO4]. Five hundred micrograms of protein in lysis buffer was
incubated overnight at 4°C with 8 μg of anti–HO-1 antibody. Pro-
tein G Agarose beads (Invitrogen) were added to each tube for 3 hours
at 4°C. Beads were washed with ice-cold lysis buffer. Fifty micrograms
of the lysate was used as input. Immune complexes were analyzed by
immunoblot with anti-STAT3 and anti–HO-1 antibodies.
Immunofluorescence and Microscopy
Cells were seeded in 12-well plates at a density of 1 × 105 cells per
well on coverslips overnight. Cells were treated as described above
and were fixed in ice-cold methanol and permeabilized for 10 min-
utes with 0.5% Triton X-100/phosphate-buffered saline (PBS),
washed with PBS, and then blocked with 5% BSA/PBS. Cells were
incubated overnight with primary antibodies diluted in 4% BSA and
0.1% Tween 20 in PBS. Cells were then washed with PBS and incu-
bated with fluorescent secondary antibodies. Negative controls were
carried out using PBS instead of primary antibodies. Cells were
washed, mounted, and imaged by confocal laser scanning microscopy,
which was performed with an Olympus Fluo view FV 1000 micro-
scope, using an Olympus 60×/1.20 NA UPLAN APO water immer-
sion objective. Excitation and emission filters were given as follows:
Alexa Fluor 488: excitation, 488 nm; emission, band pass 505 to 525 nm;
Alexa Fluor 555: excitation, 543 nm; emission, band pass 560 to 620 nm.
Wide field microscopy was carried out using an Olympus IX71
microscope with a 40× 1.15 numerical aperture (NA) water immer-
sion objective, a mercury arc lamp excitation, and suitable filters
(camera: Hamamatsu Orca CCD C4742-95).
Image Processing
Confocal and wide field microscope images were processed for
presentation with ImageJ (http://rsb.info.nih.gov, National Institutes
of Health). Background of each channel was subtracted, and in some
cases a median filter (radius, 1 pixel), was applied only for presentation.
Co-localization Analysis
After background subtraction and segmentation of each cell, we
applied the ImageJ plug-in Intensity correlation to calculate Manders
coefficients. Product of the Differences from the Mean (PDM) and
frequency plot graphs were performed also with ImageJ plug-ins. We
analyzed 14 to 26 cells of each treatment.
STAT3 Translocation Experiments by Microscopy
Image processing was performed by creation of a homemade routine
using Matlab.
Segmentation (nucleus and cytoplasm). Channel backgrounds
(median) were subtracted and a median filter (1 pixel) was applied.
Segmentation was performed for each cell using the HO-1 (green)
images. After cell segmentation, the nucleus was defined as the pixels
where the 4′,6-diamidino-2-phenylindole (DAPI) signal (blue) was
higher than 60 counts. This segmentation leaded to the creation of
two masks: “cell” and “nucleus.”
Estimation of the cellular distribution of STAT3. Values in the
“nucleus” and in the “cell” were summed for the red channel (STAT3).
Therefore, we obtained the total STAT3 (STAT3t) and the nuclear
STAT3 (STAT3n). To compute the distribution of the red fluores-
cence, we calculated the ratio STAT3n/STAT3t. This “internal calibra-
tion” approach was chosen to remove the influence of the amplifier gain
and the zoom factor for each image acquisition conditions.
Chromatin Immunoprecipitation
HO-1 chromatin immunoprecipitation (ChIP) experiments were
conducted as previously described [18] using a polyclonal anti–HO-1
antibody and a nonspecific control antibody (GAL4 or IgG). Briefly,
treated LNCaP cells were fixed with formaldehyde and fixation was
stopped with 125 mM glycine. The cells were lysed in IP buffer [50 mM
Tris (pH 7.4), 150 mM NaCl, 5 mM EDTA (pH 8), 0.5% NP40, and
1% Triton X-100] with 1× protease inhibitor mixture (Sigma-Aldrich).
Chromatin was sheared to an average size of 300 bp by sonication using
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a Branson Sonifier Cell Disruptor. Polyclonal anti–HO-1 (12 μg) or
GAL4 (0.5 μg) antibodies were added to lysates and rotated at 4°C
overnight. Protein G Sepharose beads and 50 μl of salmon sperm
DNA (1 mg/ml; Invitrogen) were added and incubated for 3 hours
at 4°C. Immunocomplexes were washed. After reversal cross-link, the
immunoprecipitated chromatin was dissolved in 200 μl of water. Ten
percent of total protein of cross-linked lysate was used as a positive
control (total input). Immunopurified DNA was used for qPCR. Data
from ChIP assay were presented as fold enrichment (the ratio between
precipitated DNA over total input) and then relative to nonspecific
control β-globin. Primers used are located at the proximal promoter
region of the selected targets. Primer sequences were given as follows:
matrix metalloproteinase 9 (MMP9), 5′-CCCTCCCTCCCTTTCA-
TACAGTTC-3′ and 5′-GCTTACACCACCTCCTCCTCTC-3′;
cyclin D1, 5′-CCCCGCAAGGACCGACTG-3′ and 5′-AAATTC-
CAGCAGCAGCCCAAG-3′; vascular endothelial growth factor A
(VEGF-A), 5′-GGGTTGAGGGCGTTGGAG-3′ and 5′-GAGGGA-
GCAGGAAAGTGAGG-3′; uPA, 5′-TGAGGCAGTCTTAGGCA-
AGTTGG-3′ and 5′-GGCTTGTAAATTCTCCGTGCTTCC-3′;
PSA, 5′-GCTCTCCCTCCCCTTCCACAG-3′ and 5′-GGCACCC-
AGAGGCTGACCAAG-3′; β-globin, 5′-TTTGCAGCCTCACCT-
TCTTT-3′ and 5′-TGGGGGATATTATGAAGGGC-3′.
Human PCa Xenograft Model
Mice xenografts using PC3HO-1 and PC3pcDNA3 cell lines were
previously described [11].
Immunohistochemical and Immunocytochemical Analyses
Immunohistochemical and immunocytochemical techniques were
performed as previously described [10,11].
shSTAT3 Transduction Protocol
For lentivirus packaging,HEK293LTVwere transfected with 3.64 μg
of pSPAX2, 1.45μg of pMD2G, and 1.97 of μg pSEW-shSTAT3.1 plus
2.43 μg of pSEW-shSTAT3.2 or 4.4 μg of pSEW-GL2 as control using
15 μl of Lipofectamine 2000 (Invitrogen). LNCaP cells were transduced
every 24 hours for four rounds with the viral supernatant previously
filtered and 8 μg/ml polybrene. After 72-hour post-transduction, cells
were harvested for RNA isolation.
Statistical Analysis
All results are given as mean ± SD of n separate independent
experiments unless stated otherwise. Student’s t test was used to
ascertain statistical significance with a threshold of P < 0.05 (*)
and P < 0.01 (**).
Results
HO-1 Overexpression Attenuates AR Signaling
Because of the critical role of HO-1 and AR in prostate carcino-
genesis, we investigated the hypothesis that HO-1 could function as
a modulator of AR activity in response to testosterone. LNCaP cells
were co-transfected with the PSA-luc plasmid (4.3 kb PSA promoter
fragment cloned upstream of the luciferase gene) and the HO-1
expression vector. Luciferase activity was determined after testos-
terone stimulation. The transcriptional activity of the PSA promoter
induced by hormone was significantly repressed by HO-1 over-
expression (Figure 1A ). In addition, LNCaP cells were either tran-
siently transfected with an HO-1 expression vector or treated with
hemin (80 μM, 24 hours), a selective HO-1 inducer, and the levels
of PSA mRNA were assessed by reverse transcription–quantitative
PCR (RT-qPCR). As shown in Figure 1B, in both cases, PSA was
Figure 1. HO-1 down-modulates hormone-induced PSA transcrip-
tion in PCa cells. (A) LNCaP cells transiently transfected with
pcDNA3HO-1 or empty vector (pcDNA3) were transfected with the
PSA luciferase reporter plasmid. Cells were serum starved in phenol
red–free media with or without testosterone (10 μM, 24 hours).
Then, cells were lysed and luciferase activity assay was performed.
Data were normalized to total protein values. One representative
from at least three independent experiments is shown. (B) mRNA
expression levels by real-time RT-qPCR of PSA (left panel) and
HO-1 (right panel) in LNCaP cells transfected with pcDNA3HO-1
or empty vector (upper panels) or exposed to hemin (80 μM,
24 hours) or vehicle (lower panels). Data were normalized to β-actin.
One representative from at least three independent experiments is
shown. (C) PC3 cells transient transfected with the pcDNA3 AR5
expression vector (PC3 AR) and with pcDNA3HO-1 or empty vector
(pcDNA3) were transfected with the PSA luciferase reporter plas-
mid. Cells were serum starved in phenol red–free media with or
without testosterone (10 μM, 24 hours). Then, cells were lysed
and luciferase activity assay was performed. Data were normalized
to protein values. One representative from at least three indepen-
dent experiments is shown. Significant differences at **P < 0.01
and *P < 0.05.
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transcriptionally repressed when HO-1 was induced genetically or
pharmacologically (28.2% and 63.7%, respectively; P < 0.05). In
both cases, HO-1 overexpression was validated by RT-qPCR
(Figure 1B ).
To further confirm the inhibitory effect of HO-1 over AR transactiva-
tion, HO-1 overexpressing PC3 cells (PC3HO-1) and control cells
(PC3pcDNA3) were co-transfected with AR expression vector and
PSA-luc plasmid and then were exposed to testosterone or vehicle. We
found that HO-1 overexpression partially abrogated (27.3%, P < 0.05)
the hormone-induced PSA promoter activity in PC3 cells (Figure 1C ).
These data revealed that HO-1 decreases hormone-induced AR
transactivation, suggesting a direct role of HO-1 as a regulator of
AR activity in response to testosterone.
HO-1 Binds to the uPA, MMP9, and PSA Promoters and
Interacts with STAT3
We have previously reported the nuclear localization of HO-1 in
human primary prostate carcinomas [10], in hemin-treated PCa cells
and in PCa xenografts [11]. To further investigate the role of HO-1
in the nucleus, we examined the ability of HO-1 to associate to pro-
moters of genes relevant to prostate carcinogenesis, such as uPA,
MMP9, PSA, VEGF, and cyclin D1 by anti–HO-1 CHIP-qPCR.
Interestingly, HO-1 was significantly enriched at the uPA, MMP9,
and PSA proximal promoter regions in testosterone-stimulated LNCaP
cells. However, HO-1 enrichment was not detected at the VEGF and
cyclin D1 promoters (Figure 2A). β-Globin promoter was used as non-
specific enrichment. This is the first report showing HO-1 association
Figure 2. HO-1 protein binds to genes involved in prostate carcinogenesis and associates to STAT3. (A) HO-1–ChIP was conducted from
LNCaP cells exposed to testosterone (10 μM, 24 hours) or vehicle. DNA-ChIP was analyzed by qPCR using primers located at the proxi-
mal promoter region of uPA, MMP9, PSA, VEGF, and cyclin D1 genes or β-globin as negative control. Fold enrichment was calculated
normalizing data to input and GAL4 antibody. Significant difference at *P < 0.05. (B) Left panel: LNCaP cells were treated with testos-
terone (10 μM, 24 hours), hemin (80 μM, 24 hours), both or vehicle. Cell extracts were immunoprecipitated using an anti–HO-1 poly-
clonal antibody or IgG as negative control. Complexes were analyzed by sodium dodecyl sulfate–polyacrylamide gel electrophoresis/
immunoblot assay with anti-STAT3, anti-AR, and anti–HO-1 antibodies. Right panel: AR protein levels were determined by Western blot
analysis in whole-cell lysates extracted from LNCaP cells cultured with testosterone (10 μM, 24 hours), hemin (80 μM, 24 hours), both, or
vehicle. β-Actin levels are shown to control for equal loading. (C) pSTAT3Y705, STAT3, and HO-1 protein levels were determined by
Western blot analysis in whole-cell lysates extracted from control or IL-6 (10 ng/ml, 24 hours)–stimulated LNCaP cells and treated with
testosterone (10 μM, 24 hours), hemin (80 μM, 24 hours), both, or vehicle (left lower panel). β-Actin levels are shown to control for equal
loading. Bar graphs represent the quantitative measurement of pSTAT3Y705 normalized to total STAT3 (right upper panel) or STAT3
normalized to β-actin (right lower panel). The results were expressed as mean ± SEM.
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to promoters, suggesting a novel function for HO-1 in the nucleus
beyond its classic cytoplasmic role in heme degradation.
Given that HO-1 is a short protein with no DNA binding motif
[19], we next sought to test the hypothesis that HO-1 suppresses
AR transcriptional activity as a result of a protein-protein interaction.
We first analyzed the putative interactions by endogenous HO-1
co-immunoprecipitation in LNCaP cells exposed to hemin and stimu-
lated with testosterone. As shown in Figure 2B, we detected no direct
interaction between HO-1 and AR under any treatment.
Considering that STAT3 has been implicated in the pathogenesis
of PCa [13] and has been shown to interact with AR [16,20], we
investigated whether there was a direct protein-protein association
between HO-1 and STAT3, which could mediate the effect of
HO-1 in AR transcriptional activation. We detected by immunoblot
STAT3 and HO-1 co-immunoprecipitation in LNCaP cells treated
or not with hemin and/or testosterone (Figure 2B, left panel ). By
Western blot analysis, we corroborated AR induction under testos-
terone treatment (Figure 2B, right panel ). In spite of the down-
modulation of PSA (Figure 1), AR levels did not change by forcing
the expression of HO-1 (Figure 2B, right panel ), suggesting that
HO-1 was affecting a signaling pathway involved in AR activation.
HO-1 Is a Negative Regulator of STAT3
To determine if HO-1 inhibitory effect on PSA levels might involve
STAT3 signaling, we assessed whether HO-1 blocked STAT3 activa-
tion induced by IL-6, a well-known activator of STAT3 pathway in
LNCaP cells. As shown in Figure 2C , IL-6 increased STAT3 activation
(pSTAT3) and total protein (STAT3) levels in LNCaP cells. Interest-
ingly, hemin significantly reduced STAT3 phosphorylation in the pres-
ence or absence of testosterone (Figure 2C ).
Surprisingly, Western blot analysis of nuclear and cytoplasmic
protein extracts from IL-6–treated LNCaP cells revealed that hemin
exposure decreases the translocation of pSTAT3 to the nucleus, while
at the same time pSTAT3 retention is increased in the cytoplasmic
compartment (Figure 3A ). The cytoplasmic and nuclear fraction
enrichment was verified in all samples by detection of β-actin and
laminin A/C, respectively (Figure 3A ). Accordingly, quantitative
analysis of confocal immunofluorescence showed that hemin treat-
ment retained STAT3 in the cytoplasm over the predominant nuclear
localization produced by IL-6 alone (Figure 3, B and C ).
Next, we assessed whether the differences triggered by hemin in
STAT3 activation and localization could affect the expression of
STAT3 transcriptional target genes by RT-qPCR. We found that
hemin decreases Bcl-xL and cyclin D1 mRNA levels in the presence
of IL-6 (Figure 3D). As control, STAT3 expression induction by IL-6
was determined (Figure 3D).
Altogether, these data strongly demonstrated that HO-1 diminishes
AR and STAT3 transactivation in LNCaP cells.
STAT3 Mediates HO-1 Down-modulation of AR Signaling
The data support the view that STAT3 is involved in the anti-
tumorigenic function of HO-1. Therefore, to test whether STAT3
by itself could mediate HO-1 repression of PSA transcription,
LNCaP cells were co-transfected with the PSA-luc construct and
STAT3C or STAT3-DN mutants. STAT3C generates STAT3 con-
stitutively active protein as a result of substituting the cysteine resi-
dues for C661A and C663N, allowing STAT3 dimerization and
activation [21,22]. The STAT3 DN mutant cannot be phosphory-
lated on tyrosine 705, competing with the wild-type protein for the
activating kinase [23]. Figure 4A (upper left panel ) shows that
STAT3C highly increases testosterone-induced PSA promoter activ-
ity in LNCaP cells and the repressive effect of hemin in testosterone-
stimulated cells was still observed (Figure 4, upper left panel ). We also
assessed the PSA mRNA levels by RT-qPCR in the same conditions. As
shown in Figure 4A (right panel ), we further confirmed the inhibitory
effect of hemin on testosterone-induced PSA transcripts in LNCaP
cells. Accordingly, STAT3DN mutant co-transfection abolished the
induction provoked by the hormone; however, the repression exerted
by hemin is still observed (Figure 4A, upper panels). STAT3 mRNA
levels after transfection were determined by RT-qPCR (Figure 4A,
lower left panel ). In addition, HO-1 mRNA level induction by hemin
was confirmed by RT-qPCR in cells transfected with both STAT3
mutants (Figure 4A, lower right panel ).
To further validate STAT3C constitutive activation, we examined
the expression of STAT3 downstream target genes. STAT3C signif-
icantly increases the mRNA levels of uPA, survivin, and cyclin D1.
As expected, hemin significantly diminished STAT3C induction of
these target genes (Figure 4B ).
We also examined the effects of STAT3 protein knockdown by
RNA interference using a lentivirus small hairpin delivery system
on PSA expression in LNCaP cells. Exposure of cells to pSEW-
shSTAT3 significantly reduced STAT3 mRNA and protein levels
(50% and 88%, respectively, P < 0.01), which was further reflected
in PSA down-modulation compared to cells transduced with control
plasmid (pSEW-Gl2; Figure 4C ). HO-1 induction by hemin was
not affected by STAT3 down-modulation (Figure 4C ).
In summary, these data strongly suggest that HO-1 induction blocks
the STAT3 signal pathway and plays negative roles in AR transactivation.
HO-1 Induces STAT3 Cytoplasmic Retention in
Tumor Tissues and PCA Cells
As the role of STAT3 as aDNA-binding transcription factor naturally
depends on its ability to gain entrance to the nucleus [24], we test
whether HO-1 retains STAT3 in the cytoplasm and disrupts STAT3-AR
interaction. By confocal microscopy, STAT3 and AR co-localization
was evaluated in LNCaP cells treated with testosterone (to activate AR)
and stimulated with IL-6 (to activate STAT3) and exposed or not to
hemin. The images displayed in Figure 5A show a nuclear localization
of AR induced by the hormone and of STAT3 stimulated by the cyto-
kine. A high degree of co-localization between STAT3 (green) and AR
(red) signals was quantitatively observed in the overlay images (yellow).
However, a significant diminution in the nuclear co-localization of AR
and STAT3 is detected when cells were exposed to hemin, which can be
assigned to the cytoplasmic retention of STAT3 inHO-1–induced cells
(Figure 5A ). The quantitative co-localization analysis to estimate the
degree of overlap of fluorescence signals also shows a significant dim-
inution in Manders coefficient values in the presence of hemin rela-
tive to the untreated controls (0.88 ± 0.01 vs 0.91 ± 0.01, P < 0.05;
n = 25 cells, Figure 5B ). We plotted the PDM, applying an intensity
correlation analysis plug-in (Figure 5C ). In addition, frequency scatter
plots were computed (Figure 5D ), showing that while before hemin
treatment both signals were close to a line at 45°; this high correlation
is lost after HO-1 induction. Consistently, under the same experimental
conditions, STAT3 and HO-1 displayed a greater co-localization
degree in the presence of hemin with respect to controls (0.90 ± 0.01
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Figure 3. HO-1 represses IL-6–stimulated STAT3 in LNCaP cells. (A) LNCaP cells were cultured for 24 hours and then were activated with
IL-6 (10 ng/ml) and exposed to hemin (80 μM) or vehicle for 24 hours. Nuclear and cytoplasmic fractions were extracted, and
pSTAT3Y705, STAT3, and HO-1 expression were analyzed by Western blot analysis. The purity of the cytoplasmic and nuclear fractions
was verified in all samples by detection of β-actin and laminin A/C, respectively. One representative from at least three independent
experiments is shown. Bar graph represents the quantitative measurement of pSTAT3Y705 normalized to STAT3. The results were
expressed as mean ± SEM. Significant differences at **P < 0.01 and *P < 0.05. (B) STAT3 expression and cellular distribution was
visualized by immunofluorescence staining of LNCaP cells treated with IL-6 plus hemin or IL-6 alone. A representative image for each
group is shown. Cytoplasmic STAT3 retention is observed under hemin treatment. Scale bar, 10 μm. (C) Segmentation of the whole cell
and nucleus (DAPI) was performed to calculate the ratio of STAT3n/STAT3t and Stat3c/STAT3t in a cell-by-cell analysis. Quantification of
the subcellular localization of STAT3 is expressed as a percentage of STAT3 in the cytoplasm (red bar) and STAT3 in the nucleus (blue
bar). (D) mRNA expression levels of Bcl-xL, STAT3, and cyclin D1 were analyzed by real-time PCR. Data were normalized to β-actin. One
representative from at least three independent experiments is shown. Significant difference at **P < 0.01 and *P < 0.05.
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vs 0.86 ± 0.01, P < 0.001; n = 21 cells, Figure 5, E–H ). We fur-
ther confirmed STAT3 cytoplasmic retention calculating the ratio
of nuclear STAT3/total STAT3 by quantifying immunofluorescence
experiments (Figure 6). Additionally, immunocytochemistry studies
validated these findings, showing that the exclusive STAT3 nuclear
localization induced by IL-6 was impaired under hemin treatment in
cells exposed or not to testosterone (Figure 7A ). IL-6–stimulated
cells showed high nuclear and cytoplasmic staining for STAT3. This
Figure 4. HO-1 abrogates STAT3 induction and attenuates AR signaling. LNCaP cells transient transfected with a constitutively active
STAT3 mutant (pcDNA3 STAT3C) or a dominant negative mutant (pcDNA3 STAT3DN) or empty vectors (pcDNA3) were serum starved in
phenol red–free media with testosterone (10 μM, 24 hours), hemin (80 μM, 24 hours), both, or vehicle. (A) Cells were co-transfected with
the PSA luciferase reporter plasmid, and after treatment, cells were lysed and luciferase activity assay was performed (left upper panel).
Data were normalized to protein values. One representative from at least three independent experiments is shown. mRNA expression
levels of PSA and HO-1 were analyzed by real-time PCR (right upper and lower panels). Levels of STAT3 mRNA for pcDNA3 STAT3C and
pcDNA3 STAT3DN transfection were analyzed by real-time PCR (left lower panel). Data were normalized to β-actin. One representative
from at least three independent experiments is shown. (B) mRNA expression levels of uPA, survivin, and cyclin D1 in pcDNA3 STAT3C
LNCaP cells or controls (pcDNA3) were analyzed by RT-qPCR. Data were normalized to β-actin. One representative from at least three
independent experiments is shown. (C) LNCaP cells transduced with pSEW-GL2 and pSEW-shSTAT3 were treated with testosterone
(10 μM, 24 hours), hemin (80 μM, 24 hours), both, or vehicle. mRNA expression levels of PSA and HO-1 were analyzed by real-time PCR
(right and left upper panels). Levels of STAT3mRNA and proteins for pSEW-G2 and pSEW-shSTAT3 transduction were analyzed by real-time
PCR (left lower panel) and Western blot analysis (right lower panel). Data were normalized to β-actin. One representative from at least three
independent experiments is shown. Significant differences at **P < 0.01 and *P < 0.05.
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Figure 5. HO-1 abrogates nuclear STAT3 and AR co-localization. (A) Hemin treatment disrupts the nuclear co-localization between STAT3
and AR. LNCaP cells were treated with hemin (80 μM, 24 hours) or vehicle and activated with testosterone (10 μM, 24 hours) and
stimulated with IL-6 (10 ng/ml, 24 hours). Cells were fixed and stained with anti-STAT3 primary antibody and a secondary antibody
conjugated to Alexa Fluor 488 (green fluorescence) and anti-AR primary antibody and a secondary antibody conjugated to Alexa Fluor
555 (red fluorescence). Cells were imaged by confocal microscopy. The degree of overlap between the green and red channels is ob-
served in the overlay. (B) Manders coefficient (STAT3/AR) in individual cells was calculated. Significant difference at *P < 0.05.
(C) Representative PDM graphs are shown. (D) Frequency scatter plots were performed with the ImageJ intensity correlation analysis
plug-in (channel 1, Alexa Fluor 488; channel 2, Alexa Fluor 555). (E) Hemin treatment increases the cytoplasmic co-localization of STAT3
and HO-1. LNCaP cells were treated with hemin (80 μM, 24 hours) or vehicle and activated with testosterone (10 μM, 24 hours) and
stimulated with IL-6 (10 ng/ml, 24 hours). Cells were fixed and stained with anti–HO-1 primary antibody (green fluorescence) and anti-
STAT3 primary antibody (red fluorescence) and imaged by confocal microscopy. The degree of overlap between the green and red
channels is observed in the overlay. (F) Manders coefficient (STAT3/HO-1) in individual cells was calculated. Significant difference at
*P < 0.001. (G) Representative PDM graphs are shown. (H) Frequency scatter plots of one slice per treatment were performed with the
ImageJ intensity correlation analysis plug-in (channel 1, Alexa Fluor 488; channel 2, Alexa Fluor 555).
Neoplasia Vol. 14, No. 11, 2012 HO-1 and STAT3 in Prostate Cancer Elguero et al. 1051
staining was almost abolished under hemin treatment. In accordance,
the same pattern was observed in cells further exposed to testosterone.
The differential STAT3 immunoreactivity was also quantitatively
assessed (Figure 7B).
To further explore the cross talk between HO-1 and STAT3 in vivo,
we examined STAT3 expression in PC3 tumors overexpressing HO-1
grown (subcutaneously for 23 days) as xenografts in nude mice [11].
Both PC3HO-1 and PC3pcDNA3 tumors showed STAT3 nuclear
and cytoplasmic immunostaining. However, HO-1–overexpressing
tumors clearly displayed STAT3 cytoplasmic retention compared to
controls (Figure 7C ). PC3pcDNA3 tumor showed positive STAT3
immunostaining, predominantly nuclear, in a moderate number of
tumor cells, while in the PC3HO-1 xenografts, a large number of
tumor cells displayed positive STAT3 cytoplasmic immunoreactivity.
Accordingly, STAT3 mRNA levels were significantly decreased
(20%, P < 0.05) in PC3HO-1 tumors compared to control xenografts
(Figure 7D). As previously reported, PC3HO-1 tumors grown for
23 days were smaller [11] and less vascularized [12]. Thus, the HO-1
impairment of the STAT3 signaling axis backs up the anti-tumoral
effect of HO-1 in PCa previously reported [11,12].
Discussion
During PCa progression, tumors initially respond to androgen ablation
therapy but often become castration resistant [25] and several mecha-
nisms may underlie this progression [26]. One of those mechanisms
involves the activation of alternative cellular signaling pathways that
switch on the AR and consequently the AR-regulated transcription,
even in the absence of hormone [27]. Among them, IL-6 was recog-
nized to activate the AR signaling in LNCaP, an androgen-sensitive cell
line that expresses AR [28]. IL-6 is frequently elevated in patients with
prostate carcinoma [29] and is thought to influence tumor growth
through autocrine or paracrine loops [14,30] through activation of the
Janus kinase (JAK)-STAT pathway [31]. Androgens were demonstrated
to enhance the IL-6/STAT3 response [20,32] and activated STAT3 is
frequently found in prostate carcinomas [15].
Figure 6. HO-1 retains STAT3 in the cytoplasm under testosterone treatment. (A) STAT3 expression and cellular distribution was visu-
alized by immunofluorescence staining of LNCaP cells treated with IL-6 (10 ng/ml, 24 hours) plus hemin (80 μM, 24 hours) or IL-6 alone
under testosterone (10 μM, 24 hours) exposure. A representative image for each group is shown. Cytoplasmic STAT3 retention is
observed under hemin treatment. Scale bar, 10 μm. (B) Cell-by-cell quantification of the subcellular localization of STAT3 expressed
as a percentage of STAT3 signal in the nuclear compartment (blue bar) or in the cytoplasm (red bar) is shown.
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In the present study, we determined whether HO-1 was able to
provoke changes either in the levels of transcription regulators or
affecting their interactions that in turn would modify the signal of
routing within several networks. In this context, we explored whether
HO-1 is altering the AR-mediated response by affecting STAT3
signaling. We focused on STAT3 pathway, as it is critically associated
to PCa progression [33,34].
Herein, we demonstrate for the first time that HO-1 induction
represses PSA transcription in PCa cells, indicating that HO-1
down-modulates AR signaling and further supporting the nuclear
role of HO-1. By immunoprecipitation, we also determined that
HO-1 interacts with STAT3. We then analyzed STAT3 cellular
status in HO-1–induced PCa cells and in HO-1–overexpressing
tumors generated in nude mice. Our results clearly demonstrated
that HO-1 induction retained cytoplasmic localization of STAT3.
In vitro studies showed that HO-1 overexpression also reduced
STAT3 signaling in PCa.
We previously reported the nuclear expression ofHO-1 in human pri-
mary prostate carcinomas [10]. In PCa cell lines, we further confirmed
that HO-1 up-regulation induced its nuclear localization and inhibited
cell proliferation, migration, and invasion. Moreover, it impaired tumor
growth in vivo and downregulated the expression of target genes associ-
ated with inflammation and angiogenesis [11]. Among them, IL-6
expression was diminished in PCa cells with higher levels of HO-1.
We recently confirmed that HO-1 forced expression in PC3 cells, a
highly aggressive and invasive PCa cell line, repressed VEGF-A,
Figure 7. Forced expression of HO-1 correlates with reduced STAT3 expression in PCa cells and xenografts. (A) Immunocytochemical
analysis of STAT3 in IL-6 (10 ng/ml, 24 hours)–stimulated LNCaP cells treated with testosterone (10 μM, 24 hours), hemin (80 μM,
24 hours), both, or vehicle. The STAT3 nuclear localization induced by IL-6 was impaired under hemin treatment in cells exposed or
not to testosterone. Original magnification, ×40. (B) The differential STAT3 immunoreactivity was quantitatively assessed. The results
were expressed as mean ± SEM. Significant difference at **P < 0.01. (C) Athymic nude (nu/nu) mice were injected subcutaneously in
the right flank with PC3 cells overexpressing HO-1 (PC3HO-1) or control (PC3pcDNA3). Animals were sacrificed after 23 days and tumors
were excised. Immunohistochemical staining of STAT3 in PC3HO-1 and PC3pcDNA3 tumors was performed. PC3pcDNA3 tumor (left
panel) shows positive STAT3 immunostaining, predominantly nuclear, in a moderate number of tumor cells (25×), inset: strong nuclear
immunostaining (40×). PC3HO-1 tumor (right panel) shows positive STAT3 immunostaining both in the nucleus and cytoplasm in a large
number of tumor cells (25×); inset: area showing positive cells with an intense, diffuse, and mainly cytoplasmic staining pattern (40×).
(D) Harvested tumors (PC3HO-1 and PC3pcDNA3) were snap-frozen in liquid nitrogen and subsequently processed for RNA isolation.
Total RNA was extracted, and STAT3 mRNA levels were analyzed by real-time PCR. Data were normalized to β-actin. One representative
from at least three independent experiments is shown. Significant difference at *P < 0.05.
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VEGF-C, and hypoxia inducible factor-1 α (HIF-1α) at the tran-
scriptional level and that HO-1 overexpression greatly inhibited the
VEGF promoter activity [12]. Interestingly, in vivo studies showed that
HO-1 overexpression significantly impaired the ability of early stage
PC3HO-1 xenografts to form vascular structures, with amarked decrease
in the number of small vessels and in the expression levels of endothelial
cell–specific markers such as cluster of differentiation 34 (CD34) and
VEGFR-2. These results correlated with repressed NFκB-mediated
transcription from an NFκB responsive luciferase reporter construct,
induced accumulation of inhibitor of kappa B (IκB), and decreased
IκB kinase (IKK) mRNA levels, strongly suggesting that HO-1 may
regulate angiogenesis through this pathway [12].
Given that inflammation is a critical component of tumor growth
and progression [35], the control of the inflammatory mediators plays
a pivotal role in triggering this process [36]. Highly reactive chemical
compounds, such as reactive oxygen species, produced during inflam-
mation, could cause oxidative damage to DNA in epithelial cells or
react with other cellular components initiating a free radical chain
reaction, thus sustaining the prostate carcinogenic process [7,36]. We
demonstrated that up-regulation of HO-1 correlates with reduced
levels of pro-inflammatory and pro-angiogenic factors [angiopoietin 1
(ANGPT1), angiopoietin-like 3 (ANGPTL3), chemokine (C-X-C
motif ) ligand 1 (CXCL1), CXCL3, CXCL10, and CXCL5, VEGF-D,
IL-6, IL-8, MMP9, thrombospondin 1 (THBS1), and VEGF-A]
in PCa cells. The identification of MMP9 as a downstream target of
HO-1 in PCa cells is of particular interest and suggests that increased
expression of HO-1 by PCa cells could define a less invasive and there-
fore less aggressive phenotype [11]. HO-1 expression was also reported in
other tumor types such as lymphosarcoma, breast adenocarcinoma, hepa-
toma, glioblastoma, melanoma, Kaposi sarcoma, squamous carcinoma,
pancreatic cancer, and brain tumors (for a review, see reference [8]).
These observations prompted us to explore the nature of the
molecular mechanism underlying the functional anti-tumorigenic role
of HO-1 in PCa. In this study, the involvement of STAT3 signaling in
HO-1–induced PCa cells was addressed.
Various cytokines and growth factors regulate cellular processes by
activating STAT3 phosphorylation [37], which causes dimerization
and nuclear translocation that mediates transcriptional responses to
many extracellular signals. IL-6 and other IL-6–related polypeptides
bind to the transmembrane receptors GP130 and JAK and enhance
STAT3 phosphorylation. STAT3 plays diverse roles in cellular pro-
cesses and is required for normal embryogenesis in the mouse [38].
However, a JAK/STAT noncanonical pathway has been described, in
which cytokine receptors may be dimerized in the absence of the
ligand. Instead of inducing dimerization, the ligand stabilizes a pre-
formed dimer and/or triggers a conformational change from an
inactive to an active dimer. In this model, these nonphosphorylated
nuclear STAT molecules also contribute to gene regulation [39].
STAT3 influences cell survival, metabolism, growth, differentiation,
and migration in multiple organs [40] and has been reported to
impact on epithelial repair in some organs [41]. Furthermore, the
role of STAT3 in cell migration has been demonstrated in a number
of experimental models [42], affecting cell motility through both
transcriptional and nontranscriptional pathways [41,43,44].
In advanced PCa, active STAT3 is expressed and the increased
expression of pSTAT3 in patients correlates with augmented disease
severity and shorter survival times [15,32]. The induced expression of
activated STAT3 is thought to be a consequence of the increased levels
of circulating IL-6 detected in hormone refractory PCa patients [45].
Dynamic changes in response to extracellular stimuli can occur
through several mechanisms [14]. Here, we show that HO-1 down-
modulates AR signaling by abrogating STAT3 activity. The sen-
sitization of the AR to testosterone is dependent on STAT3 because
expression of the STAT3 DN inhibits AR response to the hormone
and ectopic expression of STAT3C vector increases PSA transcription.
HO-1 induction clearly represses this activation, interfering STAT3
signaling as detected by down-modulation of the expression of STAT3
target genes.
The HO-1/STAT3 axis has also drawn attention in other malig-
nancies such as lung injury, ischemia/reperfusion injury (IRI), and
malaria. It appears that both HO-1 and carbon monoxide, one of
its catalytic products, require endothelial STAT3 to exert their protec-
tive effects, and STAT3 confers endothelial cell protection through
both HO-1–dependent and independent mechanisms. Apparently,
there is a positive feedback system between STAT3 and HO-1, in
which STAT3 activates HO-1, leading to the production of carbon
monoxide, which in turn activates STAT3. These observations delin-
eate an interdependence between HO-1 and STAT3. The speculation
relies in that the presence of this system presumably ensures optimal
activation of two vital protective pathways mediated by HO-1 and
STAT3 optimizing defense against lethal lung injury [46].
Additionally, this axis is implicated in the regulation of innate
immune responses in liver IRI, altering the phosphatidyl inositol
3-kinase (PI3K)/phosphatase and tensin homolog (PTEN) signaling,
down-regulating PI3K/Akt, and hence providing the negative feed-
back mechanism for hepatic toll-like receptor 4 (TLR4)-driven in-
flammation. These results set new grounds for innovative therapeutic
avenues to manage hepatic inflammation and IRI in liver transplant
recipients [47].
Severe malaria also shows an interesting cross talk between HO-1,
CXCL10/CXCR3, and STAT3, linking these molecules in the patho-
genesis of this disease [48].
During the past years, the cancer field has witnessed how the reg-
ulation of the tumoral immune response has step forward in cancer
immunotherapy. The comprehension of the cellular and molecular
mechanisms underlying immune cell activation and homeostasis will
unravel the intricacy of tumoral immune escape [49]. In this context,
HO-1 could also be involved in the tumoral escape, exerting a protective
action in the diseases mediated by effector T lymphocytes such as
T helper (Th) 1, Th2, and Th17 [50]. Furthermore, the constitutive
activation of STAT3 both in tumor cells and in the diverse immune cells
in the tumoral stroma also has been shown to inhibit the expression of
numerous factors and molecules necessary for immune-mediated tumor
rejection. These include chemokine (C-Cmotif ) ligand 5 (CCL5), IL-12,
tumor necrosis factor (TNF), interferon (IFN)-γ, IFN-β, CXCL10,
CD40, CD80, CD86, and major histocompatibility complex (MHC)
class II molecules [51]. These reports further point out the relevance of
HO-1/STAT3 as an interesting axis for cancer immunotherapy.
Complexes between STAT3 and AR protein in PCa were previ-
ously reported and their functionalities are affected by paracrine/
autocrine loops, which in turn activate different signaling cascades
[14]. Here, we demonstrate that HO-1 does not directly associate
to AR, but it interacts with STAT3. Our results show that hemin
treatment diminishes AR and STAT3 co-localization in the nuclear
compartment and enhances STAT3 and HO-1 co-localization in the
cytoplasm. Thus, we propose that HO-1 is influencing the associa-
tion of AR and STAT3, probably affecting the operativeness of the
active complex formed by these two proteins. The interaction between
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STAT3 andHO-1 abrogates STAT3 activation, and in this way, HO-1
induction represses AR activity, affecting PCa cells tumorigenicity.
Biological systems frequently exhibit redundancy that can explain
altered response to different factors. Thus, we cannot discard that other
signaling pathways are affected by HO-1, such as NFκB pathway. We
recently reported that the anti-angiogenic activity of HO-1 in PCa cells
is mediated by impairment of NFκB pathway [12]. Several genes in-
volved in tumorigenesis are regulated by STAT3 and NFκB, either syn-
ergistically or individually. It was recently proposed that STAT3 was
required for proper induction of IL-6 by NFκB, demonstrating that
both factors existed as identical nuclear complexes in proximal IL-6
promoters and that STAT3 participates in the nuclear retention of
NFκB [52]. These findings prompted authors to suggest that these
two oncogenic transcriptional factors are activated simultaneously by
an intrinsic mechanism during stressful conditions of cancer cells,
cooperatively inducing various survival factors [52]. Thus, we can
hypothesize that HO-1 induction down-modulates the activation and
signaling pathways of both factors, and in turn, both may contribute
to the control of PCa cell proliferation, invasion, and migration and
PCa tumor growth.
Further studies are needed to understand the complexity of the dis-
ruption of the cooperative signaling cross talk and if these evidences
could support an unprecedented role of HO-1 outlining a rationale
for its development as an anticancer target in PCa.
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